Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 9/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 9/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26462712 | 0.85 | AR (0.37) | GABRA2GABRB2GABRB3 | |
| SCHEMBL18896300 | 0.83 | CYP3A4 (0.51) | — | |
| SCHEMBL21725448 | 0.80 | PDE2A (0.55) | PDE2A | |
| SCHEMBL22222362 | 0.78 | KMT2A (0.36) | PDE2A | |
| SCHEMBL21164525 | 0.78 | KMT2A (0.36) | PDE2A | |
| SCHEMBL18638714 | 0.76 | PDE2A (0.44) | GABRA2GABRB2GABRB3PDE2A | |
| SCHEMBL22222395 | 0.72 | PDE2A (0.34) | PDE2A | |
| SCHEMBL22898345 | 0.72 | PDE2A (0.39) | GABRA2GABRB2GABRB3PDE2A | |
| SCHEMBL21725447 | 0.71 | PDE2A (0.62) | PDE2A | |
| SCHEMBL19003603 | 0.70 | PDE2A (0.43) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | GABRA2 1824/4885GABRB2 1606/4885GABRB3 1423/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | GABRA2 1824/4885GABRB2 1606/4885GABRB3 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.